PhoreMost and ThinkCyte to collaborate on AI-powered drug discovery

Published by
Cambridge Independent

By (Mike Scialom) PhoreMost and ThinkCyte are collaborating to advance AI-based drug discovery. The strategic research partnership is aimed at advancing modern phenotypic drug screening using AI. Unity Campus-based is dedicated to ‘Drugging the Undruggable’ disease targets, while Japan-based ThinkCyte KK is a biotech company pioneering novel cell analysis and sorting instruments. The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery. PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte…

Read More

See also  Commonwealth Fusion Systems Raised Another $115 Million to Reach ARC Fusion Commercialization Phase Starting 2025

Leave a Reply